Skip to main content
. Author manuscript; available in PMC: 2013 Sep 15.
Published in final edited form as: Am J Hematol. 2011 Feb 15;86(3):251–255. doi: 10.1002/ajh.21948

Figure 1.

Figure 1

Panel A shows the relationship between a 50% decrease in the FLC-diff and the overall survival (OS) from transplant among patients who survived at least 100 days posttransplant and who had a baseline FLC-diff > = 10 mg/dL. The median OS from SCT was not reached among those with a 50% decrease in FLC-diff (n = 120) compared to 20 months (95% CI; 3, 22) for the remaining patients (n = 5). Panel B shows the relationship between a 90% decrease in the FLC-diff and the OS from transplant among patients who survived at least 100 days posttransplant and who had a baseline FLC-diff > = 10 mg/dL. The median OS among those with a 90% decrease in FLC-diff (n = 77) was not reached compared to 37.4 months (95% CI; 32, 58) for the remaining patients (n = 48), P < 0.001. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]